Alessandro Cardu

Dr. Alessandro Cardu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGabriele Pintaudi
Gabriele Pintaudi
SCSalvatore Lucio Cutuli
Salvatore Lucio Cutuli
TRTommaso Rosà
Tommaso Rosà
TMTeresa Michi
Teresa Michi
ACAlessandro Cardu
Alessandro Cardu
DGDomenico Luca Grieco
Domenico Luca Grieco
Acute hypercapnic respiratory failure is a life-threatening condition caused by alveolar hypoventilation. It is mostly caused by an acute exacerbation of chronic obstructive pulmonary disease or conditions yielding muscle dysfunction. Noninvasive ventilation through a facemask is the cornerstone first-line strategy to support hypercapnic patients with acidemia, and current guidelines strongly recommend this intervention to improve survival and long-term clinical outcomes. Because of its benefits related to carbon dioxide washout from the upper airways and the enhanced comfort, high-flow nasal oxygen has been proposed as a respiratory support strategy in patients with hypercapnic respiratory failure, both as an alternative to and in combination with noninvasive ventilation. When compared to noninvasive ventilation as a first-line intervention, high-flow nasal oxygen shows a higher rate of failure. Hence, if not contraindicated, the use of noninvasive ventilation should be preferred. After the resolution of acidemia with noninvasive ventilation, high-flow nasal oxygen showed promising physiological effects compared to conventional oxygen. During weaning from mechanical ventilation in patients with or at risk of developing hypercapnia, high-flow nasal oxygen showed encouraging results, especially when applied alternating with sessions of noninvasive ventilation. Optimal settings of high-flow nasal oxygen in hypercapnic patients include the use of a smaller-size cannula, flows ranging between 30 and 40 L/min, and FiO2 adjusted to obtain SpO2 between 88% and 92%. Specific interfaces, such as asymmetric cannulas, may further enhance the benefits of a high flow in terms of carbon dioxide clearance. In this narrative review, we provide an updated overview of the physiological rationale and clinical evidence concerning the use of high-flow nasal oxygen in patients with acute hypercapnic respiratory failure.

6 November 2026 in Critical Care
Verified
Journal Article
Open access
PDF file
LCLuca Delle Cese
Luca Delle Cese
LMLuca S. Menga
Luca S. Menga
ACAlessandro Cardu
Alessandro Cardu
TRTommaso Rosà
Tommaso Rosà
VGValentina Giammatteo
Valentina Giammatteo
DGDomenico Luca Grieco
Domenico Luca Grieco
Expiratory muscle activity raises end-expiratory pleural pressure and may oppose the effects of PEEP. Whether the regional response to PEEP differs between